(Q39803214)

14 September 2017

title

After FRANCIS: next steps in the clinical evaluation of varespladib methyl (English)

1 reference

14 September 2017

Robert S Rosenson

1

1 reference

14 September 2017

publication date

1 January 2011

1 reference

14 September 2017

1 reference

14 September 2017

volume

7

1 reference

14 September 2017

issue

1

1 reference

14 September 2017

page(s)

11-18

1 reference

Early identification of atherosclerotic disease by noninvasive imaging.

14 September 2017

cites work

1 reference

https://api.crossref.org/works/10.2217%2FFCA.10.118

Imaging atherosclerotic plaque inflammation by fluorodeoxyglucose with positron emission tomography: ready for prime time?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFCA.10.118

Acute-phase reactants and coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFCA.10.118

C-reactive protein levels and outcomes after statin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFCA.10.118

Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFCA.10.118

Early C-reactive protein in the prediction of long-term outcomes after acute coronary syndromes: a meta-analysis of longitudinal studies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFCA.10.118

Atherosclerotic Vascular Disease Conference: Writing Group II: risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFCA.10.118

C-reactive protein and coronary disease: is there a causal link?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFCA.10.118

Future role for selective phospholipase A2 inhibitors in the prevention of atherosclerotic cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFCA.10.118

Phospholipase A2 inhibition and atherosclerotic vascular disease: prospects for targeting secretory and lipoprotein-associated phospholipase A2 enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFCA.10.118

Secretory phospholipase A2: a multifaceted family of proatherogenic enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFCA.10.118

Molecular mechanism for changes in proteoglycan binding on compositional changes of the core and the surface of low-density lipoprotein-containing human apolipoprotein B100.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFCA.10.118

Potent modification of low density lipoprotein by group X secretory phospholipase A2 is linked to macrophage foam cell formation.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFCA.10.118

Effects of 1-H-indole-3-glyoxamide (A-002) on concentration of secretory phospholipase A2 (PLASMA study): a phase II double-blind, randomised, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFCA.10.118

Group V phospholipase A2 induces leukotriene biosynthesis in human neutrophils through the activation of group IVA phospholipase A2

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFCA.10.118

Novel group V phospholipase A2 involved in arachidonic acid mobilization in murine P388D1 macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFCA.10.118

Regulation of macrophage foam cell formation by alphaVbeta3 integrin: potential role in human atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFCA.10.118

Effects of Varespladib Methyl on Biomarkers and Major Cardiovascular Events in Acute Coronary Syndrome Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFCA.10.118

Varespladib methyl in cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFCA.10.118

21 January 2018

Identifiers

DOI

10.2217/FCA.10.118

1 reference

14 September 2017

1 reference